Cargando…

Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report

INTRODUCTION: In the relapsed setting, arsenic trioxide remains the backbone of treatment. Scant literature exists regarding treatment of relapsed acute promyelocytic leukemia in patients with renal failure. To the best of our knowledge we are the first to report a safe and effective means of treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emmons, Gregory S, Steingart, Richard H, Stewart, James A, Mertens, Wilson C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514175/ https://www.ncbi.nlm.nih.gov/pubmed/23078653 http://dx.doi.org/10.1186/1752-1947-6-355

Ejemplares similares

Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
por: Tinajero, Jose, et al.
Publicado: (2022)

Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report
por: Lee, Hee Jeong, et al.
Publicado: (2020)

Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis
por: Au, Wing-Yan, et al.
Publicado: (2012)

Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide
por: Hashimoto, Akiko, et al.
Publicado: (2021)

Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide
por: Hashimoto, Akiko, et al.
Publicado: (2021)

A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014)

On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse
por: Kulkarni, Uday Prakash, et al.
Publicado: (2023)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens
por: Fouzia, N. A., et al.
Publicado: (2020)

Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013)

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
por: Kulkarni, Uday, et al.
Publicado: (2020)

Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line
por: Baek, Jin Ho, et al.
Publicado: (2012)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017)

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
por: Efficace, Fabio, et al.
Publicado: (2021)

Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
por: Zheng, Yu, et al.
Publicado: (2021)

Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
por: Yedjou, Clement, et al.
Publicado: (2009)

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia
por: Ganesan, S, et al.
Publicado: (2016)

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]
Publicado: (2017)

Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review
por: Mohammadi Kanesbi, Mehdi, et al.
Publicado: (2020)

Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report
por: Kojima, Minoru, et al.
Publicado: (2016)

Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia
por: Shindo, Motohiro, et al.
Publicado: (2012)

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
por: Kayser, Sabine, et al.
Publicado: (2021)

Unusual massive bone marrow fibrosis in acute promyelocytic leukemia following arsenic trioxide therapy
por: Venkatesan, S., et al.
Publicado: (2015)

Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
por: Li, Tao, et al.
Publicado: (2018)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro
por: Noguera, Nélida I., et al.
Publicado: (2017)

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia
por: Weinhäuser, Isabel, et al.
Publicado: (2020)

Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia
por: Zhou, Guang-Biao, et al.
Publicado: (2005)

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022)

Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient
por: Iriyama, Noriyoshi, et al.
Publicado: (2012)

Erythema multiforme due to arsenic trioxide in a case of acute promyelocytic leukemia: A diagnostic challenge
por: Badarkhe, Girish V., et al.
Publicado: (2016)

Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells
por: Wang, Shuping, et al.
Publicado: (2015)

Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman
por: Cochet, Claire, et al.
Publicado: (2020)

Melatonin enhances arsenic trioxide-induced cytotoxicity by modulating autophagy in an acute promyelocytic leukemia cell line
por: Wei, Xia, et al.
Publicado: (2019)

Severe Acute Axonal Neuropathy following Treatment with Arsenic Trioxide for Acute Promyelocytic Leukemia: a Case Report
por: Kühn, Marcus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9a2g89pnlra3clng4sstrfavh5